Sharda Cropchem Ltd Q2 FY26 Earnings Analysis

- Sharda Cropchem Limited expects FY 2026 revenue growth of around 15%. - In Q1 FY 2026, revenue grew 25% year-on-year to Rs. 985 crores, with overall volume growth of 13%. - Agrochemical segment volume grew 11%, while non-agrochemical segment volume grew 59% year-on-year. - The company maintains a robust registration pipeline with over 1,000 product registrations pending approval, supporting future growth. - CAPEX planned at Rs. 400-450 crores for the year to support product registrations and expansion. - European region, a major contributor, showed strong sales growth of 43% in revenues. - Pricing improvements are slow but steady, supporting margin and revenue growth. - No major pre-stocking or destocking seen; demand growth is driven by genuine market demand. - The management does not foresee disruption in growth due to tariffs or geopolitical issues, maintaining steady business operations.

- Sharda Cropchem Limited expects revenue growth of around 15% for FY 2026. - EBITDA margin guidance is maintained in the range of 15% to 18%, with a possibility to touch the higher side. - Gross margins are expected to sustain at around 35%-36% for the full year, driven by stable business conditions and favorable forex movements. - PAT grew 424% YoY in Q1 FY26, supported by strong revenue and margin expansion. - The company is investing in registrations and planned CAPEX of Rs. 400-450 crores to support future growth. - No adverse inventory impacts or order cancellations anticipated, implying business stability. - Currency exchange benefits, especially from Euro appreciation, are contributing positively. - Management is optimistic about steady price improvements and strong demand on the ground rather than inventory restocking. - With strong cash reserves and disciplined working capital management, the company is well-positioned for sustained profitability growth.

- CAPEX for Q1 FY26 stood at Rs. 114 crores. - Planned CAPEX for the full year FY26 is Rs. 400-Rs. 450 crores. - The company aims to increase product registrations backed by this CAPEX. - No significant strategic changes reported in registration pipeline strategy, continuing with the existing registrations unless products get banned. - The company is focused on running business comfortably and maintaining liquidity to withstand any adverse situations. - Dividend payouts have been liberalized recently, with two dividends declared in the last quarter. Overall, the company is investing heavily towards registrations and growth with a strong CAPEX plan while maintaining healthy liquidity and shareholder rewards.

- There is no explicit mention of any current or planned fundraising through debt or equity in the document. - The company remains debt-free as of June 30, 2025, with a strong cash and liquid investment position of Rs. 791 crores. - Management emphasizes maintaining a comfortable cash position to manage adverse situations and support business continuity. - CAPEX planned for FY 2026 is Rs. 400-Rs. 450 crores, funded internally from cash resources. - There is no indication of raising fresh debt or equity in the near term. - The focus appears to be on organic growth and prudent cash management without additional fundraising.

- As of 30th June 2025, Sharda Cropchem has 2,981 registrations. - Additionally, there are 1,021 applications for product registrations at the approval stage. - There was no specific mention of the current or expected order book value or pending orders in the Q1 FY26 earnings call transcript. - The company indicated strong registration pipeline and continued pursuit of registrations once initiated, unless regulatory bans occur. - The management did not elaborate quantitatively on pending orders or order backlog during the call.